STOCK TITAN

Nuvalent Inc - NUVL STOCK NEWS

Welcome to our dedicated news page for Nuvalent (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvalent's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvalent's position in the market.

Rhea-AI Summary
Nuvalent, Inc. announces pricing of public offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.28%
Tags
-
Rhea-AI Summary
Nuvalent, Inc. has announced a public offering of $300.0 million of its shares of Class A common stock. The offering is subject to market conditions and there is no assurance as to whether or when it may be completed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary
Nuvalent announces encouraging preliminary data from Phase 1 trial of NVL-655 for ALK-positive NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
Rhea-AI Summary
Nuvalent, Inc. announces preliminary data from Phase 1 trial of NVL-655 for ALK-positive NSCLC and other solid tumors. Positive preliminary activity demonstrated with partial responses in 45% of response-evaluable patients. Early indicators of CNS activity observed. Dose-proportional exposure and reductions in ALK fusion and mutation variants shown. Well-tolerated with generally mild adverse events. No MTD identified. Phase 1 ongoing to determine RP2D. Conference call and webcast scheduled for October 13th at 8:00 am EDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.57%
Tags
-
Rhea-AI Summary
Nuvalent to present preliminary dose-escalation data of NVL-655 at AACR-NCI-EORTC Symposium on October 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
conferences clinical trial
-
Rhea-AI Summary
Nuvalent announces initiation of Phase 2 trial for NVL-520 in ROS1-positive NSCLC and other solid tumors, following FDA alignment on recommended Phase 2 dose of 100 mg daily.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
Rhea-AI Summary
Nuvalent, Inc. to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
Rhea-AI Summary
Nuvalent, Inc. (NUVL) to participate in investor conferences. CEO and CFO to attend Wedbush PacGrow Healthcare Conference on August 8 and Canaccord Genuity 43rd Annual Growth Conference on August 9. Live webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences
Nuvalent Inc

Nasdaq:NUVL

NUVL Rankings

NUVL Stock Data

4.20B
32.77M
3.7%
108.89%
10.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About NUVL

nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.